Tetrahydrocannabutol
Studies and references cited across this article, graded by evidence strength.
Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.
Data points an editor reviewed and accepted for publication.
Value Provenance
Dosing
oraltrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 3 mg | 3 mg | low |
| Low | 3–12 mg | 3–12 mg | low |
| Common | 12–30 mg | 12–30 mg | low |
| Strong | 30–70 mg | 30–70 mg | low |
| Heavy | 70+ mg | 70+ mg | low |
| Editorial | All oral dose values from commercial vendor content (Binoid CBD guide): threshold/beginner ~3 mg, light 3-12 mg, common 12-30 mg, strong 30-70 mg, heavy 70+ mg. No controlled human dosing data exist for THCB at any dose. Work-notes specify these ranges with confidence=low and community/vendor source only. | ||
ReasoningReasoningAll oral dose values from commercial vendor content (Binoid CBD guide): threshold/beginner ~3 mg, light 3-12 mg, common 12-30 mg, strong 30-70 mg, heavy 70+ mg. No controlled human dosing data exist for THCB at any dose. Work-notes specify these ranges with confidence=low and community/vendor source only. Evidence basis: community_consensus_small | |||
Duration
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 30–60 minutes | 30–60 minutes | low |
| Editorial | User reports describe THCB as a 'creeper compound' with oral onset of 30-60 minutes. Source: vendor guides and forum reports (Binoid, Canatura). No controlled data. | ||
ReasoningReasoningUser reports describe THCB as a 'creeper compound' with oral onset of 30-60 minutes. Source: vendor guides and forum reports (Binoid, Canatura). No controlled data. Evidence basis: community_consensus_small | |||
| Totaltrace | 4–8 hours | 4–8 hours | low |
| Editorial | User reports indicate total oral duration of approximately 4-8 hours. Source: vendor guides and forum reports. No controlled data. | ||
ReasoningReasoningUser reports indicate total oral duration of approximately 4-8 hours. Source: vendor guides and forum reports. No controlled data. Evidence basis: community_consensus_small | |||
inhaled
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 5–10 minutes | 5–10 minutes | low |
| Editorial | No THCB-specific inhaled onset data. Inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, onset of psychoactive effects within minutes). Work-notes propose 5-10 min by THC analogy. | ||
ReasoningReasoningNo THCB-specific inhaled onset data. Inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, onset of psychoactive effects within minutes). Work-notes propose 5-10 min by THC analogy. Evidence basis: structural_analogy | |||
| Totaltrace | 2–4 hours | 2–4 hours | low |
| Editorial | No THCB-specific inhaled duration data. Inferred from Δ9-THC inhaled duration (~2-4 hours). Work-notes propose this range by THC analogy. | ||
ReasoningReasoningNo THCB-specific inhaled duration data. Inferred from Δ9-THC inhaled duration (~2-4 hours). Work-notes propose this range by THC analogy. Evidence basis: structural_analogy | |||
Safety
Toxicity Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Acute | low | low | low |
| Chronic | low | low | low |
| Organs Affected | cardiovascular, neurological | cardiovascular, neurological | low |
| Editorial | Work-notes specify acute=low, chronic=low-to-moderate, both by class analogy with Δ9-THC. Applying evidence discount rule: work-notes already set at low for acute; chronic downgraded from low-to-moderate to low given entirely structural inference with no THCB-specific data. Reference compound: Δ9-THC. No adverse event case reports, no LD50, no controlled toxicity studies for THCB. | ||
ReasoningReasoningWork-notes specify acute=low, chronic=low-to-moderate, both by class analogy with Δ9-THC. Applying evidence discount rule: work-notes already set at low for acute; chronic downgraded from low-to-moderate to low given entirely structural inference with no THCB-specific data. Reference compound: Δ9-THC. No adverse event case reports, no LD50, no controlled toxicity studies for THCB. Evidence basis: structural_analogy | |||
Dependence Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Physical | low | low | low |
| Psychological | low | low | low |
| Compulsive Redosing | low | low | low |
| Dose Escalation | moderate | moderate | low |
| Editorial | All dependence data class-inferred from Δ9-THC (reference compound). Work-notes specify physical=low, psychological=low-to-moderate (downgraded to low per evidence discount for structural inference), compulsive redosing=low, dose escalation=moderate. No THCB-specific dependence or withdrawal studies exist. Tai et al. 2015 THC tolerance data used as basis. | ||
ReasoningReasoningAll dependence data class-inferred from Δ9-THC (reference compound). Work-notes specify physical=low, psychological=low-to-moderate (downgraded to low per evidence discount for structural inference), compulsive redosing=low, dose escalation=moderate. No THCB-specific dependence or withdrawal studies exist. Tai et al. 2015 THC tolerance data used as basis. Evidence basis: structural_analogy | |||
Withdrawal Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Severity | mild | mild | low |
| Symptoms | irritability, insomnia, anxiety, appetite disturbance, restlessness | irritability, insomnia, anxiety, appetite disturbance, restlessness | low |
| Fatal | No | No | low |
| Medical Supervision | Not required | Not required | low |
| Editorial | Cannabis-type withdrawal syndrome inferred from Δ9-THC by class analogy (Cochrane review, Lucas et al. 2018). Work-notes specify onset 1-2 days, duration 1-2 weeks, severity mild-to-moderate. Downgraded to mild given structural inference discount and partial agonist status. | ||
ReasoningReasoningCannabis-type withdrawal syndrome inferred from Δ9-THC by class analogy (Cochrane review, Lucas et al. 2018). Work-notes specify onset 1-2 days, duration 1-2 weeks, severity mild-to-moderate. Downgraded to mild given structural inference discount and partial agonist status. Evidence basis: structural_analogy | |||
Tolerance Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Buildup | moderate | moderate | low |
| Half-life | 5 days | 5 days | low |
| Full Reset | 21 days | 21 days | low |
| Cross-tolerances | Δ9-THC, Δ8-THC, THCP, THCV, THCH, synthetic cannabinoids | Δ9-THC, Δ8-THC, THCP, THCV, THCH, synthetic cannabinoids | low |
| Editorial | Work-notes specify moderate buildup, 3-7 day half-life (midpoint 5 days used), 2-4 week full reset (midpoint 21 days). All values from Tai et al. 2015 THC tolerance data. Reference compound: Δ9-THC. No THCB-specific tolerance studies exist. | ||
ReasoningReasoningWork-notes specify moderate buildup, 3-7 day half-life (midpoint 5 days used), 2-4 week full reset (midpoint 21 days). All values from Tai et al. 2015 THC tolerance data. Reference compound: Δ9-THC. No THCB-specific tolerance studies exist. Evidence basis: structural_analogy | |||
Effects & Profile
Contraindications
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| psychiatric Psychotic disorders (schizophrenia, schizoaffective disorder)trace | absolute | absolute | low |
| Editorial | Class-level contraindication from CB1 agonist cannabinoids. Article prose and research output both confirm psychosis precipitation risk from CB1 agonism (Lucas et al. 2018, Br J Clin Pharmacol). | ||
ReasoningReasoningClass-level contraindication from CB1 agonist cannabinoids. Article prose and research output both confirm psychosis precipitation risk from CB1 agonism (Lucas et al. 2018, Br J Clin Pharmacol). | |||
| psychiatric First-degree family history of psychotic disorderstrace | relative | relative | low |
| Editorial | Class-level relative contraindication for all CB1 agonist cannabinoids. Work-notes list this explicitly. Inferred from Δ9-THC epidemiological data. | ||
ReasoningReasoningClass-level relative contraindication for all CB1 agonist cannabinoids. Work-notes list this explicitly. Inferred from Δ9-THC epidemiological data. | |||
| pregnancy breastfeeding Pregnancy and lactationtrace | absolute | absolute | low |
| Editorial | Class-level absolute contraindication from THC reproductive toxicity data. Article prose cites Lucas et al. 2018. Work-notes list this as absolute. | ||
ReasoningReasoningClass-level absolute contraindication from THC reproductive toxicity data. Article prose cites Lucas et al. 2018. Work-notes list this as absolute. | |||
| cardiovascular Unstable cardiovascular diseasetrace | relative | relative | low |
| Editorial | Class-level relative contraindication for CB1 agonist cannabinoids. Work-notes and article prose both list this. Inferred from Δ9-THC cardiovascular adverse effect profile. | ||
ReasoningReasoningClass-level relative contraindication for CB1 agonist cannabinoids. Work-notes and article prose both list this. Inferred from Δ9-THC cardiovascular adverse effect profile. | |||
| other Concurrent anticoagulant therapy (warfarin, coumarins)trace | relative | relative | low |
| Editorial | Class-level CYP2C9 interaction prediction from Bansal et al. 2022 and Nasrin et al. 2021 (Drug Metab Dispos). Work-notes list this explicitly as relative contraindication. | ||
ReasoningReasoningClass-level CYP2C9 interaction prediction from Bansal et al. 2022 and Nasrin et al. 2021 (Drug Metab Dispos). Work-notes list this explicitly as relative contraindication. | |||
| other Narrow-therapeutic-index CYP3A4 substrates (tacrolimus, cyclosporine)trace | relative | relative | low |
| Editorial | Class-level CYP3A4 interaction prediction from THC analogs. Work-notes and article prose both list this. Inferred from Bansal et al. 2022, Nasrin et al. 2021. | ||
ReasoningReasoningClass-level CYP3A4 interaction prediction from THC analogs. Work-notes and article prose both list this. Inferred from Bansal et al. 2022, Nasrin et al. 2021. | |||
| hepatic Hepatic impairmenttrace | relative | relative | low |
| Editorial | Class-level hepatic contraindication for CYP-metabolized cannabinoids. Work-notes list this explicitly. Inferred from THC hepatic metabolism via CYP2C9. | ||
ReasoningReasoningClass-level hepatic contraindication for CYP-metabolized cannabinoids. Work-notes list this explicitly. Inferred from THC hepatic metabolism via CYP2C9. | |||
Timeline Phases
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Resolutiontrace | 3600–7200 sec(i=0.50) | 3600–7200 sec(i=0.50) | low |
| Editorial | Oral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. | ||
ReasoningReasoningOral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. Evidence basis: community_consensus_small | |||
| Onsettrace | 1800–3600 sec(i=0.10) | 1800–3600 sec(i=0.10) | low |
| Editorial | Oral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. | ||
ReasoningReasoningOral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. Evidence basis: community_consensus_small | |||
| Come uptrace | 1800–3600 sec(i=0.40) | 1800–3600 sec(i=0.40) | low |
| Editorial | Oral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. | ||
ReasoningReasoningOral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. Evidence basis: community_consensus_small | |||
| Peaktrace | 3600–10800 sec(i=1.00) | 3600–10800 sec(i=1.00) | low |
| Editorial | Oral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. | ||
ReasoningReasoningOral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. Evidence basis: community_consensus_small | |||
| Afterglowtrace | 7200–14400 sec(i=0.20) | 7200–14400 sec(i=0.20) | low |
| Editorial | Oral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. | ||
ReasoningReasoningOral timeline derived from user reports describing 30-60 min onset ('creeper compound') and 4-8 hour total duration (vendor guides, Binoid/Canatura). Phase breakdown (come_up, peak, resolution, afterglow) extrapolated from Δ9-THC oral pharmacokinetics (Tmax 1-6 hours) and work-notes phase durations. No controlled THCB-specific duration data exist. Evidence basis: community_consensus_small | |||
inhaled
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Peaktrace | 1800–5400 sec(i=1.00) | 1800–5400 sec(i=1.00) | low |
| Editorial | All inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. | ||
ReasoningReasoningAll inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. Evidence basis: structural_analogy | |||
| Afterglowtrace | 3600–10800 sec(i=0.15) | 3600–10800 sec(i=0.15) | low |
| Editorial | All inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. | ||
ReasoningReasoningAll inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. Evidence basis: structural_analogy | |||
| Onsettrace | 60–300 sec(i=0.20) | 60–300 sec(i=0.20) | low |
| Editorial | All inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. | ||
ReasoningReasoningAll inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. Evidence basis: structural_analogy | |||
| Come uptrace | 300–900 sec(i=0.60) | 300–900 sec(i=0.60) | low |
| Editorial | All inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. | ||
ReasoningReasoningAll inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. Evidence basis: structural_analogy | |||
| Resolutiontrace | 1800–3600 sec(i=0.40) | 1800–3600 sec(i=0.40) | low |
| Editorial | All inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. | ||
ReasoningReasoningAll inhaled timeline data inferred from Δ9-THC inhaled pharmacokinetics (Tmax ~10 min, total 2-4 hours) and work-notes phase durations. No THCB-specific inhaled duration data exist. Reference compound: Δ9-THC. Ranges widened slightly to account for uncertainty. Evidence basis: structural_analogy | |||
Dose Tier Summaries
Mild mood elevation and subtle body relaxation characterize the light dose range. Sensory perception may be gently enhanced — colors slightly more vivid, music marginally more engaging. Cognitive function is largely preserved, consistent with user reports of a "clear-headed" quality at lower doses. Physically, mild body warmth and relaxation are typical. Dry mouth is common. Motor coordination remains largely intact, though subtle slowing may be perceptible. The experience is functional and social. Appetite may increase mildly. Duration commitment is moderate — expect 4–6 hours via oral administration before returning to baseline.
Work-notes outline for light tier, supplemented by user reports of clear-headed quality and vendor dosing guides. All values class-inferred from Δ9-THC partial agonist profile.
ReasoningReasoning
Work-notes outline for light tier, supplemented by user reports of clear-headed quality and vendor dosing guides. All values class-inferred from Δ9-THC partial agonist profile.
Evidence basis: structural_analogy
Minimal perceptible effects at the threshold dose — a subtle shift in mood or body awareness without clear intoxication. Experienced cannabinoid users may not notice any change. There is no distinct euphoria or cognitive alteration, though a faint warmth or lightness in the body may register. Physically, effects are negligible. Slight dry mouth may occur in sensitive individuals. No motor impairment or sedation is expected at this level. Onset is gradual, particularly via oral administration — THCB is described as a "creeper compound," and threshold effects may take 45–60 minutes to become apparent. Functional capacity is fully preserved.
No controlled human dose-response data for THCB. Threshold description extrapolated from work-notes outline, user reports describing subtle onset, and Δ9-THC class analogy. Vendor data (Binoid) suggests ~3 mg as beginner dose.
ReasoningReasoning
No controlled human dose-response data for THCB. Threshold description extrapolated from work-notes outline, user reports describing subtle onset, and Δ9-THC class analogy. Vendor data (Binoid) suggests ~3 mg as beginner dose.
Evidence basis: structural_analogy
Noticeable euphoria, relaxation, and analgesia define the common dose range. Sensory enhancement becomes more apparent — music enhancement, color enhancement, and taste enhancement are typical. Time alteration manifests as subjective slowing. Thought deceleration and mild thought connectivity may emerge. Physically, body high and muscle relaxation are prominent. Dry mouth is expected. Mild motor control impairment and dizziness may occur. Appetite enhancement is common. The partial CB1 agonist ceiling begins to manifest — effects plateau rather than escalating linearly with dose. This is a full but manageable cannabinoid experience. Expect 4–8 hours of effects via oral ingestion. Driving and operating machinery are unsafe.
Work-notes common tier outline, expanded with effects taxonomy names from the effects profile. Partial agonist ceiling note from pharmacology section. Duration from user reports (4–8 hours oral).
ReasoningReasoning
Work-notes common tier outline, expanded with effects taxonomy names from the effects profile. Partial agonist ceiling note from pharmacology section. Duration from user reports (4–8 hours oral).
Evidence basis: structural_analogy
Pronounced euphoria and sedation with significant cognitive alteration. Time alteration is more intense, and thought disorganization or confusion may occur. Anxiety and paranoia become possible, particularly in susceptible individuals or unfamiliar settings. Memory suppression is more evident, and introspective thinking may deepen. Physically, motor control impairment is significant — coordination is notably impaired. Sedation dominates over stimulation. Body high is intense, and spatial disorientation may occur. Dizziness and dry mouth are prominent. Functional capacity is substantially reduced. The partial agonist ceiling may limit maximum intensity compared to equivalent doses of full CB1 agonists like Δ9-THC, but subjective impairment is still considerable. Commit to 6–8 hours.
Work-notes strong tier outline, expanded with taxonomy effects. Anxiety/paranoia dose-dependence noted in both user reports and article prose. Partial agonist ceiling from pharmacology data.
ReasoningReasoning
Work-notes strong tier outline, expanded with taxonomy effects. Anxiety/paranoia dose-dependence noted in both user reports and article prose. Partial agonist ceiling from pharmacology data.
Evidence basis: structural_analogy
Intense intoxication with pronounced disorientation, significant anxiety or paranoia risk, and substantial cognitive and motor impairment. Confusion, amnesia, and spatial disorientation are likely. Depersonalization and derealization may occur at this level. The experience can be overwhelming and distressing, particularly for those with lower cannabinoid tolerance. Physically, sedation is dominant. Motor control impairment is severe — standing and walking may be difficult. Nausea and dizziness are possible. Tachycardia may be noticeable. The partial agonist ceiling may limit maximal intensity compared to equivalent doses of full CB1 agonists, but this is not a safety guarantee. Product variability — including Δ8 vs Δ9 isomers and synthesis byproducts — makes dose predictability poor at this level. Allow 8+ hours for full resolution.
Work-notes heavy tier outline with product variability warning. All effects class-inferred from Δ9-THC at high doses plus partial agonist pharmacology caveat. No controlled data at any dose level for THCB.
ReasoningReasoning
Work-notes heavy tier outline with product variability warning. All effects class-inferred from Δ9-THC at high doses plus partial agonist pharmacology caveat. No controlled data at any dose level for THCB.
Evidence basis: structural_analogy
History
backfill Jun 4, 2026
Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.
Sources
- [1]moderateIsolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal Cannabis sativa Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-TetrahydrocannabinolLinciano P, Citti C, Luongo L, Belardo C, Maione S, Vandelli MA, Forni F, Gigli G, Laganà A, Montone CM, Cannazza G · 2020 · Journal of Natural Products
- [2]strongA novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-TetrahydrocannabiphorolCitti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G · 2019 · Scientific Reports
- [3]strongIdentification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexolLinciano P, Citti C, Russo F, Tolomeo F, Laganà A, Capriotti AL, Luongo L, Iannotta M, Belardo C, Maione S, Forni F, Vandelli MA, Gigli G, Cannazza G · 2020 · Scientific Reports
- [4]moderateIdentification of Δ8-THC and Δ9-THC Analogs with Different Alkyl Chain Lengths in Oil Products Distributed on the InternetTanaka R, Kikura-Hanajiri R · 2024 · Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
- [5]moderateRepeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific mannerTai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE · 2015 · Pharmacological Research
- [6]moderateAn emerging trend in Novel Psychoactive Substances (NPSs): designer THCCaprari C, Ferri E, Vandelli MA, Citti C, Cannazza G · 2024 · Journal of Cannabis Research
- [7]moderateAnalysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analogCitti C, Linciano P, Forni F, Vandelli MA, Gigli G, Laganà A, Cannazza G · 2019 · Journal of Pharmaceutical and Biomedical Analysis
- [8]moderatePhytocannabinoids: Origins and BiosynthesisGülck T, Møller BL · 2020 · Trends in Plant Science
- [9]moderateMicrobial biosynthesis of rare cannabinoidsYan C, Okorafor IC, Johnson CW, Houk KN, Garg NK · 2024 · Journal of Industrial Microbiology & Biotechnology
- [10]moderateStructure-activity relationships for 1',1'-dimethylalkyl-Delta8-tetrahydrocannabinolsHuffman JW, Miller JR, Liddle J, Yu S, Thomas BF, Wiley JL, Martin BR · 2003 · Bioorganic & Medicinal Chemistrypubmed 126286662 claims checked2 partial
- [11]weak
- [12]moderateCannabis sativa: The Plant of the Thousand and One MoleculesAndre CM, Hausman JF, Guerriero G · 2016 · Frontiers in Plant Science
- [13]moderateModulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal HypersensitivityAnand U, Anand P, Sodergren MH · 2025 · Journal of Pain Research
- [14]moderateReceptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and EpilepsySenn L, Cannazza G, Biagini G · 2020 · Pharmaceuticals
- [15]moderateIdentification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor CannabinoidsLiu C, Puopolo T, Li H, Cai A, Seeram NP, Ma H · 2022 · Molecules
- [16]strongPharmacokinetics of cannabinoidsMcGilveray IJ · 2005 · Pain Research and Managementpubmed 162374774 claims checked3 verified1 inconclusive
- [17]strongThe pharmacokinetics and the pharmacodynamics of cannabinoidsLucas C, Galettis P, Schneider J · 2018 · British Journal of Clinical Pharmacology
- [18]moderateCharacterizing and Quantifying Extrahepatic Metabolism of (-)-Δ9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, (±)-11-Hydroxy-Δ9-THCKumar AR, Patilea-Vrana GI, Anoshchenko O, Unadkat JD · 2022 · Drug Metabolism and Disposition
- [19]moderateComprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver MicrosomesBansal S, Paine MF, Unadkat JD · 2022 · Drug Metabolism and Disposition
- [20]moderateTetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabisGoullé JP, Guerbet M · 2014 · Bulletin de l'Academie nationale de medecinepubmed 26427296no claims checked
- [21]moderateCannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug InteractionsNasrin S, Watson CJW, Perez-Paramo YX, Lazarus P · 2021 · Drug Metabolism and Dispositiondoi.org/10.1124/dmd.121.000442pubmed 344936025 claims checked2 verified1 partial1 inconclusive1 not supported
- [22]moderateComprehensive LC-MS-MS analysis of THC isomers, analogs, homologs, and metabolites in blood and urineMuir LS, Doumit SE, Seither JZ, Knittel JL, Walterscheid JP, Karschner EL · 2025 · Journal of Analytical Toxicology
- [23]strongPharmacotherapies for cannabis use disorder.Spiga F, Parkhouse T, Tang VM, Savovic J, Le Foll B, Nielsen S · 2025 · Cochrane Database of Systematic Reviews
Claim Verification
Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.
summary9 claims5verified1partial3inconclusive
verifiedTHCB binds the human CB1 receptor with high affinity (Ki = 15 nM) and functions as a partial CB1 agonist[1]model confidence 98%
Abstract directly states CB1 Ki=15 nM and that the tetrad test showed partial CB1 agonism — both key assertions in the claim are confirmed.
CB1 Ki=15 nM, CB2 Ki=51 nM. Tetrad test showed partial CB1 agonism.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveTHCB was first isolated and pharmacologically evaluated in 2020 by Linciano, Citti, and colleagues at the University of Modena and Reggio Emilia from the Italian pharmaceutical-grade Cannabis sativa FM2 cultivar[1]model confidence 65%
The abstract confirms isolation and characterization from Cannabis sativa FM2, consistent with being the primary isolation paper. However, the specific year (2020), institution name (University of Modena and Reggio Emilia), and 'Italian pharmaceutical-grade' characterisation are paper metadata not present in the abstract text.
Isolation and characterization of Δ9-THCB from Cannabis sativa FM2.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThe discovery was part of a systematic effort that also identified Δ9-THCP (C7 chain) and Δ9-THCH (C6 chain), mapping the full phytocannabinoid alkyl homolog series from C3 to C7[2]model confidence 60%
Abstract confirms THCP (C7 chain) and side-chain SAR context, but does not mention Δ9-THCH (C6 chain) or the mapping of a C3-to-C7 homolog series. Only the THCP part of the claim is verifiable from this abstract.
Isolation of Δ9-THCP (C7 chain) from Cannabis sativa FM2. Side chain length directly influences CB1 activity.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedThe discovery was part of a systematic effort that also identified Δ9-THCP (C7 chain) and Δ9-THCH (C6 chain), mapping the full phytocannabinoid alkyl homolog series from C3 to C7[3]model confidence 92%
Abstract confirms identification of THCH (hexyl/C6) and explicitly references THCB as part of the expanding homolog series (butyl, pentyl, hexyl, heptyl), directly supporting the systematic series narrative.
Identifies CBDH and Δ9-THCH (hexyl analogs) in Cannabis sativa FM2. THCB explicitly referenced as part of the expanding homolog series (butyl, pentyl, hexyl, heptyl).
checked by claude-sonnet-4-6 · May 11, 2026
partialSince approximately 2021, THCB products — including both Δ8 and Δ9 isomers — have appeared on recreational markets.[4]model confidence 82%
Abstract confirms both Δ8-THCB and Δ9-THCB in recreational market products, which supports market presence. However, the abstract dates this to 2022–2023, not 'approximately 2021,' creating a material discrepancy in the stated timeline.
Identified Δ8-THCB and Δ9-THCB in internet-sold oil products in Japan from 2022-2023.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveCompetitive radioligand binding yields CB1 Ki = 15 nM and CB2 Ki = 51 nM, values described as comparable to Δ9-THC under the same assay conditions[1]model confidence 70%
Abstract directly confirms CB1 Ki=15 nM and CB2 Ki=51 nM. However, the specific characterisation 'described as comparable to Δ9-THC under the same assay conditions' and the THC reference values are not mentioned in the abstract.
CB1 Ki=15 nM, CB2 Ki=51 nM.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedIn mice, THCB produces a partial cannabinoid tetrad response (hypolocomotion, catalepsy, antinociception, hypothermia) and demonstrates analgesic and anti-inflammatory activity in the formalin model[1]model confidence 90%
Abstract confirms both the tetrad test (with partial CB1 agonism) and the formalin test in vivo. The four tetrad components listed are the canonical standard tetrad and consistent with partial agonism described.
Formalin test in vivo. Tetrad test showed partial CB1 agonism.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedDependence and withdrawal have not been studied; by class analogy with Δ9-THC, CB1 receptor downregulation with repeated use and a mild-to-moderate cannabis-type withdrawal syndrome are expected[5]model confidence 85%
Abstract confirms region-specific CB1 receptor downregulation with repeated THC administration, supporting the class-analogy mechanism claim. The withdrawal syndrome inference is speculative in the claim, consistent with the 'by class analogy' framing.
Region-specific CB1 receptor downregulation in hypothalamus.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedProducts on the unregulated market may contain Δ8-THCB (semi-synthetic) and the synthesis byproduct Δ11-THCB, whose safety profiles are entirely unknown[4]model confidence 93%
Abstract confirms identification of Δ8-THCB and Δ11-THCB (as synthesis byproduct) in internet-sold products. The 'unknown safety profiles' is not contradicted.
Identified Δ8-THCB and Δ9-THCB in internet-sold oil products in Japan from 2022-2023. Δ11-THCB identified as synthesis byproduct.
checked by claude-sonnet-4-6 · May 11, 2026
history7 claims4verified3inconclusive
inconclusiveΔ9-Tetrahydrocannabutol was first isolated, structurally elucidated, and pharmacologically characterized by Linciano, Citti, Luongo, Belardo, Maione, Vandelli, Forni, Gigli, Laganà, Montone, and Cannazza in a paper received by the Journal of Natural Products in September 2019 and published in January 2020[1]model confidence 60%
Abstract confirms the paper is the primary isolation paper for THCB from FM2. However, the full author list, journal name, submission date (September 2019), and publication date (January 2020) are metadata not present in the abstract text.
Isolation and characterization of Δ9-THCB from Cannabis sativa FM2.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThe compound was identified through HPLC-HRMS screening of minor cannabinoid fractions, and its structure was confirmed by stereoselective synthesis yielding the (−)-trans enantiomer, with absolute configuration verified by electronic circular dichroism (ECD).[1]model confidence 60%
Abstract confirms the isolation and characterization but provides no detail on HPLC-HRMS methodology, stereoselective synthesis, enantiomeric resolution, or ECD verification. These technical details require the full paper.
Isolation and characterization of Δ9-THCB from Cannabis sativa FM2.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedConcurrently, Citti and colleagues isolated cannabidibutol (CBDB), the CBD butyl analog[7]model confidence 97%
Abstract directly confirms isolation and characterization of CBDB (cannabidibutol), the CBD butyl analog.
Isolation and characterization of CBDB (cannabidibutol), the CBD butyl analog, from hemp extract.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedIn 2020, the group further identified Δ9-THCH and cannabidihexol (CBDH), the hexyl (C6) series members[3]model confidence 92%
Abstract confirms identification of CBDH and Δ9-THCH (hexyl analogs) in Cannabis sativa FM2. Year (2020) is metadata not in the abstract but the substances and their series membership are confirmed.
Identifies CBDH and Δ9-THCH (hexyl analogs) in Cannabis sativa FM2.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedForensic analyses in Japan (2022–2023) confirmed the presence of both isomers in commercial oil products[4]model confidence 98%
Abstract directly confirms both Δ8-THCB and Δ9-THCB identified in internet-sold oil products in Japan from 2022-2023.
Identified Δ8-THCB and Δ9-THCB in internet-sold oil products in Japan from 2022-2023.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedForensic analysis has also identified Δ11-THCB as a minor byproduct of Δ8-THCB synthesis[4]model confidence 97%
Abstract directly states Δ11-THCB was identified as a synthesis byproduct.
Δ11-THCB identified as synthesis byproduct.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveTHCB occurs naturally in Cannabis sativa at trace concentrations, arising from the same terpene + polyketide biosynthetic pathway as THC but with a butyric acid (C4) rather than hexanoic acid (C6) starter unit feeding through the olivetolic acid cyclase pathway[8]model confidence 60%
Abstract confirms the review covers phytocannabinoid biosynthesis including polyketide and terpenoid routes. However, the specific detail about butyric acid vs. hexanoic acid starter units and olivetolic acid cyclase is not stated in the abstract.
Review of phytocannabinoid biosynthesis pathways including polyketide and terpenoid routes.
checked by claude-sonnet-4-6 · May 11, 2026
chemistry4 claims1partial3inconclusive
partialStructure-activity relationship studies on Δ8-THC dimethylalkyl analogs established that alkyl side chains ranging from C3 to C10 all support high CB1 affinity, with optimal affinity in the C4–C8 range[10]model confidence 80%
Abstract confirms SAR study with C2-C12 chains and optimal affinity/potency with C4-C10 — not C4-C8 as the claim states. The claim also states C3 to C10 all support high affinity, but the abstract shows optimal starts at C4, not C3.
SAR study of dimethylalkyl-Δ8-THC series with C2-C12 side chains. Optimal CB1 affinity and in vivo potency with C4-C10 chains.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThe stereochemistry was confirmed by Linciano and colleagues through stereoselective synthesis via direct condensation of 5-butylbenzene-1,3-diol (butylresorcinol) with (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol using Lewis acid catalysis, followed by HCl addition and base-catalyzed elimination, achieving 91% yield[1]model confidence 60%
Abstract confirms isolation and characterization from FM2 but contains no detail on synthesis route, reaction conditions, or yield. These specifics are in the full paper body.
Isolation and characterization of Δ9-THCB from Cannabis sativa FM2.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveBoth Δ8-THCB and Δ9-THCB positional isomers have been identified in commercial products — Δ9-THCB places the double bond between C-9 and C-10, while Δ8-THCB places it between C-8 and C-9.[4]model confidence 65%
Abstract confirms both isomers identified in commercial products, supporting the existence claim. However, the specific double bond positions (C9-C10 vs C8-C9) are structural chemistry details not stated in the abstract.
Identified Δ8-THCB and Δ9-THCB in internet-sold oil products in Japan from 2022-2023.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThe compound arises biosynthetically from a butyric acid starter unit (rather than the hexanoic acid that feeds the THC/CBD pathway), processed through the same enzymatic cascade involving olivetolic acid cyclase, a prenyltransferase (geranylpyrophosphate attachment), and a tetrahydrocannabinolic acid synthase homolog.[8]model confidence 58%
Abstract confirms the review covers phytocannabinoid biosynthesis pathways (polyketide and terpenoid routes), but the specific enzymatic cascade and starter unit details in the claim are not stated in the abstract.
Review of phytocannabinoid biosynthesis pathways including polyketide and terpenoid routes.
checked by claude-sonnet-4-6 · May 11, 2026
pharmacology19 claims8verified1partial9inconclusive1not supported
inconclusiveThese affinities are described as comparable to (−)-trans-Δ9-THC, which showed CB1 Ki ≈ 10 nM under the same assay conditions[1]model confidence 60%
Abstract confirms the THCB Ki values but does not mention a THC reference Ki of ≈10 nM or explicitly state comparability to THC. This specific datum would be in the full paper text.
CB1 Ki=15 nM, CB2 Ki=51 nM.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedCompetitive radioligand binding assays yielded Ki = 15 nM at CB1 and Ki = 51 nM at CB2[1]model confidence 99%
Abstract directly and unambiguously states CB1 Ki=15 nM and CB2 Ki=51 nM.
CB1 Ki=15 nM, CB2 Ki=51 nM.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThese affinities are described as comparable to (−)-trans-Δ9-THC, which showed CB1 Ki ≈ 10 nM under the same assay conditions[2]model confidence 55%
This is the THCP paper (CB1 Ki=1.2 nM for THCP), not the THCB paper. A THC reference Ki of ≈10 nM is not stated in this abstract, and the claim specifically concerns THCB-assay comparability.
Isolation of Δ9-THCP (C7 chain) from Cannabis sativa FM2. CB1 Ki=1.2 nM.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveMolecular docking studies identified key hydrogen bond interactions between THCB and the CB1 orthosteric pocket that parallel those of THC.[1]model confidence 65%
The abstract makes no mention of molecular docking or hydrogen bond interactions. This detail would be found in the full paper body.
Isolation and characterization of Δ9-THCB from Cannabis sativa FM2. CB1 Ki=15 nM, CB2 Ki=51 nM.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedThe partial agonist designation derives from in vivo functional data: in the standard cannabinoid tetrad test in mice (hypolocomotion, catalepsy, antinociception, hypothermia), Δ9-THCB produced cannabimimetic effects but with less full-agonist efficacy than reference compounds[1]model confidence 90%
Abstract states 'tetrad test showed partial CB1 agonism,' directly supporting the mechanism by which the partial agonist designation was reached (in vivo tetrad, incomplete response).
Tetrad test showed partial CB1 agonism.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThis contrasts with the longer-chain homolog Δ9-THCP (C7 chain, CB1 Ki = 1.2 nM), which produced a complete tetrad response consistent with full agonism[2]model confidence 65%
Abstract confirms THCP CB1 Ki=1.2 nM and that the tetrad test demonstrated cannabimimetic activity. However, it does not explicitly state that THCP produced a 'complete' tetrad response or that it is a full agonist — these specific characterisations are not in the abstract.
CB1 Ki=1.2 nM. Tetrad test demonstrated cannabimimetic activity.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveIn the formalin test in mice, THCB demonstrated both analgesic and anti-inflammatory properties, reducing both acute (early phase, neurogenic) and inflammatory (late phase) pain responses[1]model confidence 65%
Abstract confirms the formalin test was conducted in vivo, but provides no detail on early vs. late phase responses or the magnitude of effects. These specifics would require the full paper.
Formalin test in vivo.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedAnand and colleagues included THCB among ten minor cannabinoids tested in an in vitro model of neuronal hypersensitivity relevant to neuropathic pain, suggesting peripheral analgesic modulation beyond the CB1/CB2 axis.[13]model confidence 88%
Abstract directly confirms ten minor cannabinoids were tested in a neuronal hypersensitivity model for neuropathic pain. The 'suggesting peripheral analgesic modulation' is the article's interpretive framing, not a fact claim against the abstract.
Ten minor cannabinoids tested for analgesic effects in neuronal hypersensitivity model (neuropathic pain). Results from in vitro assay.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedPhytocannabinoids with structural similarity to THC can interact with TRPV1, TRPV2, GPR55, GPR18, GABA-A receptors, and voltage-gated sodium channels[14]model confidence 95%
Abstract explicitly lists all the receptors/channels named in the claim: GPR55, GPR18, TRPV1/2, GABAAR, VGSC as targets for phytocannabinoids.
Review of CB1, CB2, GPR55, GPR18, TRPV1/2, GABAAR, VGSC as targets for phytocannabinoids.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedA non-cannabinoid-receptor activity of note: Liu and colleagues screened a library of minor cannabinoids against SARS-CoV-2 main protease (Mpro) and found THCB to be the most potent inhibitor in the library (IC₅₀ = 3.62 µM), outperforming cannabigerolic acid (IC₅₀ = 14.40 µM)[15]model confidence 92%
Abstract directly confirms THCB as the most active Mpro inhibitor with IC50=3.62 µM. The cannabigerolic acid comparator is not mentioned in the abstract but the primary factual assertions about THCB are confirmed.
Tetrahydrocannabutol was the most active Mpro inhibitor (IC50=3.62 μM).
checked by claude-sonnet-4-6 · May 11, 2026
verifiedBy analogy with Δ9-THC: inhaled bioavailability is approximately 25–30%, with Tmax around 10 minutes and rapid onset of psychoactive effects[16]model confidence 93%
Abstract confirms THC bioavailability ~30% inhaled and peak plasma at ~10 min post-inhalation, directly supporting both key parameters in the claim.
THC bioavailability ~30% inhaled, 4-12% oral. Peak plasma ~152 ng/mL at ~10 min post-inhalation.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveBy analogy with Δ9-THC: inhaled bioavailability is approximately 25–30%, with Tmax around 10 minutes and rapid onset of psychoactive effects[17]model confidence 55%
This abstract covers general cannabinoid PK/PD with CYP interactions and contraindications, but does not specifically state inhaled bioavailability percentages or inhaled Tmax values.
Review of cannabinoid PK/PD. THC and CBD hepatically metabolized. CYP enzyme inhibition/induction potential.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedOral bioavailability is considerably lower (4–12%) and highly variable, with Tmax of 1–6 hours; the extended oral duration reflects first-pass hepatic metabolism generating an active 11-hydroxy metabolite[16]model confidence 88%
Abstract directly confirms 4-12% oral bioavailability and the 11-OH-THC active metabolite. The oral Tmax of 1-6 hours is not stated but the other key assertions are confirmed.
THC bioavailability ~30% inhaled, 4-12% oral. 11-OH-THC active metabolite.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveOral bioavailability is considerably lower (4–12%) and highly variable, with Tmax of 1–6 hours; the extended oral duration reflects first-pass hepatic metabolism generating an active 11-hydroxy metabolite[17]model confidence 55%
This abstract does not state specific oral bioavailability values or oral Tmax. It covers general cannabinoid hepatic metabolism but not the specific PK parameters claimed.
Review of cannabinoid PK/PD. THC and CBD hepatically metabolized.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveTHC distributes widely due to high lipophilicity, with adipose tissue serving as a long-term storage reservoir; less than 1% of the administered dose reaches the brain at peak plasma concentration.[17]model confidence 50%
Abstract does not mention lipophilic distribution, adipose storage, or the '<1% to brain' figure. These specific pharmacokinetic details are not in this abstract.
Review of cannabinoid PK/PD. THC and CBD hepatically metabolized. CYP enzyme inhibition/induction potential.
checked by claude-sonnet-4-6 · May 11, 2026
partialΔ9-THC is primarily metabolized by CYP2C9 (both intestinal and hepatic) to 11-hydroxy-THC (active metabolite), then to 11-nor-9-carboxy-THC (inactive)[18]model confidence 78%
Abstract confirms intestinal CYP2C9 (fm=0.89) as primary and 11-OH-THC formation. However, it states CYP3A in fetal liver — not CYP2C9 — for the hepatic route, contradicting 'both intestinal and hepatic' for CYP2C9. The further step to THC-COOH is also not confirmed.
THC primarily metabolized by CYP2C9 in intestine (fm=0.89), CYP3A in fetal liver. 11-OH-THC metabolized by CYP3A and UGT2B7.
checked by claude-sonnet-4-6 · May 11, 2026
not supportedΔ9-THC is primarily metabolized by CYP2C9 (both intestinal and hepatic) to 11-hydroxy-THC (active metabolite), then to 11-nor-9-carboxy-THC (inactive)[19]model confidence 88%
cited source's abstract does not support this claim — flagged for editorial review
This abstract is about CYP enzyme inhibition BY THC (THC inhibits CYP2C9, CYP3A, CYP1A2), not about the enzymes that metabolize THC. It does not confirm CYP2C9 as the primary metabolising enzyme for THC.
THC inhibits CYP2C9 (diclofenac AUC x6.6 oral) > CYP3A > CYP1A2 at clinical doses.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedCYP3A contributes, particularly in fetal liver[18]model confidence 97%
Abstract directly states 'CYP3A in fetal liver,' precisely matching the claim.
CYP3A in fetal liver.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThe terminal half-life of THC is approximately 20–30 hours, reflecting redistribution from fat stores rather than metabolic clearance.[16]model confidence 60%
Abstract confirms adipose storage and weeks-long metabolite elimination but does not state a specific terminal half-life value of 20-30 hours.
Widely distributed, body fat as long-term storage. Metabolites eliminated via feces and urine for weeks.
checked by claude-sonnet-4-6 · May 11, 2026
receptor pharmacology5 claims2verified1partial2inconclusive
inconclusiveThe sole published binding dataset for Δ9-THCB derives from the Linciano et al. isolation paper, using competitive radioligand displacement assays against human CB1 and CB2 receptors expressed in CHO cells:[1]model confidence 60%
Abstract confirms this is the primary characterization paper with CB1/CB2 binding data. However, 'sole published,' 'CHO cells,' and 'competitive radioligand displacement' are specific details not confirmed in the abstract alone.
Isolation and characterization of Δ9-THCB from Cannabis sativa FM2. CB1 Ki=15 nM, CB2 Ki=51 nM.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveFor reference, the same laboratory reported Δ9-THC CB1 Ki ≈ 10 nM under matched conditions in their companion THCP paper[2]model confidence 55%
Abstract for the THCP paper reports THCP CB1 Ki=1.2 nM but does not state a THC reference Ki value of ≈10 nM.
Isolation of Δ9-THCP (C7 chain) from Cannabis sativa FM2. CB1 Ki=1.2 nM.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedIntrinsic efficacy (Emax relative to a full agonist reference) has not been quantified in a cell-based functional assay; the partial agonist designation rests on the incomplete tetrad response in vivo rather than on direct measurement of receptor-level signaling efficacy.[1]model confidence 85%
Abstract describes only in vivo tetrad and formalin data; no cell-based functional assay data is mentioned, consistent with the claim that partial agonism is designated from in vivo data only.
Formalin test in vivo. Tetrad test showed partial CB1 agonism.
checked by claude-sonnet-4-6 · May 11, 2026
partialThe butyl side chain occupies the same hydrophobic channel as THC's pentyl chain, with the one-carbon reduction producing minimal steric penalty — consistent with SAR data from Huffman et al. demonstrating that C3 through C10 alkyl chains all support high CB1 affinity in the Δ8-THC dimethylalkyl series.[10]model confidence 78%
Abstract confirms the SAR study covers C2-C12 chains with optimal affinity C4-C10. The claim states 'C3 through C10 all support high CB1 affinity,' but optimal per abstract starts at C4, not C3. C3 is not stated to be in the high-affinity range.
SAR study of dimethylalkyl-Δ8-THC series with C2-C12 side chains. Optimal CB1 affinity and in vivo potency with C4-C10 chains.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedPhytocannabinoids with similar dibenzopyran scaffolds interact with TRPV1 (vanilloid receptor), TRPV2, GPR55, GPR18, GABA-A receptors, and voltage-gated sodium channels[14]model confidence 95%
Abstract explicitly lists all receptor/channel targets in the claim: GPR55, GPR18, TRPV1/2, GABAAR, VGSC.
Review of CB1, CB2, GPR55, GPR18, TRPV1/2, GABAAR, VGSC as targets for phytocannabinoids.
checked by claude-sonnet-4-6 · May 11, 2026
neuroscience1 claim1inconclusive
inconclusiveIn this system, postsynaptic neurons synthesize endocannabinoids (anandamide, 2-arachidonoylglycerol) on demand, which travel retrogradely to presynaptic CB1 receptors, suppressing neurotransmitter release (both glutamate and GABA, depending on the synapse).[17]model confidence 50%
Abstract covers cannabinoid PK/PD generally but does not describe the retrograde endocannabinoid signaling mechanism, the specific endocannabinoids (AEA, 2-AG), or the glutamate/GABA neurotransmitter suppression detail.
Review of cannabinoid PK/PD. THC and CBD hepatically metabolized. CYP enzyme inhibition/induction potential.
checked by claude-sonnet-4-6 · May 11, 2026
pharmacokinetic detail6 claims3verified1partial1inconclusive1not supported
verifiedAll values sourced from THC pharmacokinetic reviews.[16]model confidence 95%
Abstract confirms this is a pharmacokinetics review for cannabinoids including THC, directly supporting the attribution.
THC bioavailability ~30% inhaled, 4-12% oral. Peak plasma ~152 ng/mL at ~10 min post-inhalation.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedAll values sourced from THC pharmacokinetic reviews.[17]model confidence 93%
Abstract confirms this is a comprehensive PK/PD review for cannabinoids including THC, directly supporting the attribution.
Review of cannabinoid PK/PD. THC and CBD hepatically metabolized.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedΔ9-THC undergoes primary oxidative metabolism via CYP2C9 at C-11, generating the pharmacologically active 11-hydroxy-THC, which is subsequently oxidized to the inactive 11-nor-9-carboxy-THC (THC-COOH)[18]model confidence 82%
Abstract confirms CYP2C9 as primary metaboliser in intestine (fm=0.89) and 11-OH-THC formation. The further step to THC-COOH is not explicitly confirmed but 11-OH-THC's subsequent metabolism by CYP3A and UGT2B7 is mentioned, consistent with the pathway.
THC primarily metabolized by CYP2C9 in intestine (fm=0.89). 11-OH-THC metabolized by CYP3A and UGT2B7.
checked by claude-sonnet-4-6 · May 11, 2026
not supportedCYP2C9 is the dominant enzyme in both intestinal and hepatic first-pass metabolism; CYP3A4 contributes a secondary pathway[19]model confidence 88%
cited source's abstract does not support this claim — flagged for editorial review
This abstract describes THC inhibiting CYP2C9 (not being metabolized by it). The paper is about CYP inhibition by THC — a pharmacodynamic effect — not about the enzymes responsible for THC's own metabolism. It does not confirm CYP2C9 as a metabolising enzyme.
THC inhibits CYP2C9 (diclofenac AUC x6.6 oral) > CYP3A > CYP1A2 at clinical doses.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveBy analogy with Δ9-THC and Δ8-THC analogs, THCB is predicted to competitively inhibit CYP2C9 and CYP3A4, with additional inhibition of CYP2B6[21]model confidence 65%
Abstract confirms THC inhibits CYP2C9 and CYP2B6, supporting those parts of the claim. CYP3A4 is not listed in this abstract (CYP1A2, 2B6, 2C9, 2D6 are given), so the CYP3A4 inhibition assertion is not supported here.
THC inhibits CYP1A2, 2B6, 2C9, 2D6.
checked by claude-sonnet-4-6 · May 11, 2026
partialClinically relevant oral interactions would be expected for narrow-therapeutic-index CYP2C9 substrates (warfarin, diclofenac, phenytoin) and CYP3A4 substrates (midazolam, tacrolimus, cyclosporine)[21]model confidence 75%
Abstract confirms CYP2C9 inhibition and potential interactions with CYP2C9 substrates (supporting warfarin/diclofenac/phenytoin). CYP3A4 is not listed in this abstract, so the CYP3A4 substrate claim (midazolam, tacrolimus, cyclosporine) is not supported.
THC inhibits CYP1A2, 2B6, 2C9, 2D6. Basic static modeling suggests potential interactions with drugs metabolized by CYP2B6, 2C9, 2D6.
checked by claude-sonnet-4-6 · May 11, 2026
effects overview1 claim1inconclusive
inconclusiveUser reports describe a cannabinoid experience qualitatively similar to Δ9-THC but with a reportedly "clear-headed" quality and a slower onset profile, particularly via oral administration[6]model confidence 58%
Abstract confirms the review covers subjective effects from user reports for THC-like cannabinoids including THCB, but the specific qualitative characterizations ('clear-headed' quality, 'slower onset') are not stated in the abstract.
Covers chemistry, synthesis, pharmacology, analytical methods, and subjective effects from user reports.
checked by claude-sonnet-4-6 · May 11, 2026
safety20 claims8verified3partial8inconclusive1not supported
inconclusiveBy class analogy with Δ9-THC, the following adverse effects are expected at pharmacologically active doses: tachycardia, transient hypotension, impaired cognition, impaired motor coordination, anxiety, and paranoia (dose-dependent)[17]model confidence 55%
Abstract mentions cardiovascular and psychiatric contraindications, broadly consistent with tachycardia/anxiety, but does not enumerate the specific adverse effect list. The specific claims require full paper text.
Contraindications: psychiatric, cardiovascular, renal, hepatic illness.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedPsychosis precipitation in vulnerable individuals (personal or family history of psychotic disorders) is a recognized risk of CB1 agonism[17]model confidence 82%
Abstract explicitly lists psychiatric illness as a contraindication, directly supporting the claim that psychiatric risk (including psychosis precipitation) is recognized for cannabinoids.
Contraindications: psychiatric, cardiovascular, renal, hepatic illness.
checked by claude-sonnet-4-6 · May 11, 2026
partialRepeated high-dose cannabinoid use produces CB1 receptor downregulation in multiple brain regions, with associated cognitive impairment[5]model confidence 72%
Abstract confirms CB1 receptor downregulation but specifies only the hypothalamus (one region), not 'multiple brain regions.' Additionally, cognitive impairment is not mentioned. The title's 'brain region-specific manner' implies multiple regions, but only hypothalamus is stated.
Region-specific CB1 receptor downregulation in hypothalamus. Reduces CB1 receptor expression and function in a brain region-specific manner.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveForensic analysis of internet-sold Δ8-THCB products has identified Δ11-THCB as a minor synthesis byproduct of Lewis acid-catalyzed isomerization[4]model confidence 65%
Abstract confirms Δ11-THCB as a synthesis byproduct in internet-sold products, but does not specify the 'Lewis acid-catalyzed isomerization' mechanism. This mechanistic detail is not verifiable from the abstract.
Δ11-THCB identified as synthesis byproduct.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedA validated LC-MS/MS method can identify THCB in blood (LOD 1 ng/mL) and urine[22]model confidence 99%
Abstract directly confirms: validated LC-MS-MS method for THC homologs including THCB in blood and urine, with LOD 1 ng/mL.
Validated LC-MS-MS method for quantitative analysis of THC homologs including THCB in blood and urine. LOD 1 ng/mL.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusivePsychosis precipitation: CB1 agonism is a recognized risk factor for precipitating psychotic episodes in individuals with pre-existing vulnerability (schizophrenia spectrum, bipolar disorder, first-degree family history).[17]model confidence 60%
Abstract confirms psychiatric illness as a contraindication, but specific diagnoses (schizophrenia spectrum, bipolar disorder, first-degree family history) are not enumerated in the abstract.
Contraindications: psychiatric, cardiovascular, renal, hepatic illness.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedUser reports describe THCB-associated anxiety, paranoia, disorientation, and excessive intoxication at higher doses, consistent with the CB1 agonist class profile.[6]model confidence 85%
Abstract confirms the review covers THCB in the recreational market context and specifically includes subjective effects from user reports, directly supporting that such user reports are documented there.
Covers chemistry, synthesis, pharmacology, analytical methods, and subjective effects from user reports.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedRepeated high-dose CB1 agonist use produces tolerance via receptor downregulation (reduced CB1 density) and desensitization (uncoupling of CB1 from G-protein signaling)[5]model confidence 85%
Abstract confirms 'reduces CB1 receptor expression and function in a brain region-specific manner.' CB1 receptor downregulation (density) and functional reduction (consistent with desensitization) are both confirmed.
Reduces CB1 receptor expression and function in a brain region-specific manner.
checked by claude-sonnet-4-6 · May 11, 2026
partialIn mice, tolerance to THC's hypothermic effects develops within days of repeated administration; tolerance to locomotor suppression develops more slowly[5]model confidence 88%
Abstract confirms tolerance to hypothermia develops with repeated administration. However, the paper title explicitly states 'induces tolerance to hypothermia but NOT locomotor suppression in mice' — directly contradicting the claim that locomotor tolerance 'develops more slowly.'
Tolerance to hypothermic effects of THC develops after repeated administration. [Title: 'induces tolerance to hypothermia but not locomotor suppression in mice']
checked by claude-sonnet-4-6 · May 11, 2026
verifiedCross-tolerance between THC and other CB1 agonists is well-established — THC-tolerant individuals would be expected to show cross-tolerance to THCB.[5]model confidence 92%
Abstract directly states 'THC history causes cross-tolerance to synthetic cannabinoids,' establishing the principle the claim generalises to THCB.
THC history causes cross-tolerance to synthetic cannabinoids.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveCannabis use disorder and a characteristic withdrawal syndrome (irritability, insomnia, anxiety, appetite disturbance, restlessness) are documented for chronic high-dose THC use[23]model confidence 55%
Abstract confirms cannabis use disorder is recognised (as a pharmacotherapy target) but does not enumerate withdrawal syndrome symptoms. The specific symptom list cannot be verified from this abstract.
Cochrane review of pharmacotherapies for cannabis use disorder. No approved pharmacotherapies.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveCannabis use disorder and a characteristic withdrawal syndrome (irritability, insomnia, anxiety, appetite disturbance, restlessness) are documented for chronic high-dose THC use[17]model confidence 50%
Abstract does not describe cannabis withdrawal syndrome or its symptoms. The claim's specific symptom list is not verifiable from this abstract.
Review of cannabinoid PK/PD. Contraindications: psychiatric, cardiovascular, renal, hepatic illness.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedNo approved pharmacotherapies exist for cannabis use disorder; behavioral interventions are first-line[23]model confidence 97%
Abstract directly states 'No approved pharmacotherapies' for cannabis use disorder and that behavioral and pharmacological interventions are reviewed.
No approved pharmacotherapies. Reviews behavioral and pharmacological interventions.
checked by claude-sonnet-4-6 · May 11, 2026
partialΔ9-THC and its analogs competitively inhibit CYP2C9, CYP3A4, and CYP2B6[19]model confidence 75%
Abstract confirms THC inhibits CYP2C9 and CYP3A, but does not list CYP2B6 as inhibited. The claim includes CYP2B6 which is absent from this abstract's inhibition profile (CYP2C9>CYP3A>CYP1A2).
THC inhibits CYP2C9 (diclofenac AUC x6.6 oral) > CYP3A > CYP1A2 at clinical doses.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedΔ9-THC and its analogs competitively inhibit CYP2C9, CYP3A4, and CYP2B6[21]model confidence 88%
Abstract confirms THC inhibits CYP2B6 and CYP2C9. CYP3A4 is not listed in this abstract's inhibition profile, but CYP2B6 and CYP2C9 are directly confirmed, making the claim substantially supported.
THC inhibits CYP1A2, 2B6, 2C9, 2D6.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveAdditive CNS depression is expected with alcohol, benzodiazepines, opioids, and other cannabinoids[17]model confidence 50%
Abstract covers general PK/PD and contraindications but does not specifically describe additive CNS depression with the listed drug classes.
Review of cannabinoid PK/PD. CYP enzyme inhibition/induction potential. Contraindications: psychiatric, cardiovascular, renal, hepatic illness.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusivePregnancy and lactation (absolute): Cannabinoids cross the placenta and are excreted in breast milk; THC is associated with reduced fetal growth and neurodevelopmental effects.[17]model confidence 50%
Abstract does not mention pregnancy, lactation, placental transfer, breast milk excretion, or fetal effects. These claims are not verifiable from this abstract.
Contraindications: psychiatric, cardiovascular, renal, hepatic illness.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedConcurrent anticoagulant therapy (relative): Predicted CYP2C9 inhibition could potentiate warfarin and other coumarin anticoagulants.[21]model confidence 88%
Abstract confirms THC inhibits CYP2C9 and notes potential interactions with drugs metabolized by CYP2C9. Warfarin is a well-known CYP2C9 substrate, making this a reasonable inference directly supported by the abstract.
THC inhibits CYP1A2, 2B6, 2C9, 2D6. Basic static modeling suggests potential interactions with drugs metabolized by CYP2B6, 2C9, 2D6.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveNarrow-therapeutic-index CYP3A4 substrates (relative): Tacrolimus, cyclosporine, certain antiepileptics (carbamazepine, clobazam).[17]model confidence 50%
Abstract mentions CYP enzyme inhibition/induction potential in general, but does not specifically mention CYP3A4 inhibition or the listed narrow-therapeutic-index substrates.
CYP enzyme inhibition/induction potential.
checked by claude-sonnet-4-6 · May 11, 2026
not supportedNarrow-therapeutic-index CYP3A4 substrates (relative): Tacrolimus, cyclosporine, certain antiepileptics (carbamazepine, clobazam).[21]model confidence 85%
cited source's abstract does not support this claim — flagged for editorial review
Abstract lists THC inhibition of CYP1A2, 2B6, 2C9, 2D6 — CYP3A4 is not mentioned. The claim is specifically about CYP3A4 substrates, and this abstract provides no basis for a CYP3A4 interaction warning.
THC inhibits CYP1A2, 2B6, 2C9, 2D6. 11-OH-THC inhibits CYP2B6, 2C9, 2D6.
checked by claude-sonnet-4-6 · May 11, 2026
clinical evidence2 claims2verified
verifiedThe totality of published in vivo evidence consists of two assay paradigms performed in mice by Linciano and colleagues:[1]model confidence 88%
Abstract confirms exactly two in vivo paradigms: formalin test and tetrad test. 'Totality' of evidence in the primary isolation paper being two in vivo assays is consistent with this being the sole in vivo characterisation paper.
Formalin test in vivo. Tetrad test showed partial CB1 agonism.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedIn a separate study, Anand and colleagues tested THCB in an in vitro model of neuronal hypersensitivity relevant to neuropathic pain; detailed quantitative results are not available from the abstract.[13]model confidence 92%
Abstract confirms the study and in vitro model. The claim's note about quantitative results not being in the abstract is accurate — the abstract states results exist but doesn't quantify them.
Ten minor cannabinoids tested for analgesic effects in neuronal hypersensitivity model (neuropathic pain). Results from in vitro assay.
checked by claude-sonnet-4-6 · May 11, 2026
comparative pharmacology4 claims2verified2inconclusive
inconclusiveKi values for THCV and THCB from Linciano et al.; THC and THCP values from Citti et al.[1]model confidence 60%
Abstract confirms THCB Ki values from this paper (Linciano et al.). However, THCV is not mentioned in the abstract, so the attribution of THCV Ki to Linciano et al. cannot be verified from this abstract.
CB1 Ki=15 nM, CB2 Ki=51 nM.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedKi values for THCV and THCB from Linciano et al.; THC and THCP values from Citti et al.[2]model confidence 88%
Abstract for the Citti/THCP paper (citation [2]) confirms THCP CB1 Ki=1.2 nM, supporting attribution of THCP values to this paper.
Isolation of Δ9-THCP (C7 chain) from Cannabis sativa FM2. CB1 Ki=1.2 nM.
checked by claude-sonnet-4-6 · May 11, 2026
verifiedThe critical pharmacological distinction is functional efficacy: THCB produces a partial tetrad response while THC produces a complete response[1]model confidence 87%
Abstract confirms partial CB1 agonism in the tetrad test. The partial vs. complete framing is implicit in the 'partial agonism' designation, which inherently contrasts with full agonist reference compounds.
Tetrad test showed partial CB1 agonism.
checked by claude-sonnet-4-6 · May 11, 2026
inconclusiveThe critical pharmacological distinction is functional efficacy: THCB produces a partial tetrad response while THC produces a complete response[2]model confidence 55%
This is the THCP companion paper. It confirms cannabimimetic activity and potency higher than THC for THCP, but does not compare THCB's tetrad response to THC's complete response.
Tetrad test demonstrated cannabimimetic activity. Side chain length directly influences CB1 activity.
checked by claude-sonnet-4-6 · May 11, 2026
Coverage & Gaps
Research Trail
substance-article pipeline-v5 May 11, 2026
| Step | Source | Query | Results |
|---|---|---|---|
| 1literature search | PubMed | tetrahydrocannabutol cannabinoid | 5 results, 5 selected |
selection rationaleselection rationaleAll directly relevant to THCB pharmacology, chemistry, or toxicology | |||
| 2database lookup | PubChem | tetrahydrocannabutol / THCB / CID 6453891 | 1 result, 1 selected |
selection rationaleselection rationaleConfirmed chemical identity data for THCB | |||
| 3literature search | OpenAlex | tetrahydrocannabutol cannabinoid butyl | 10 results, 5 selected |
selection rationaleselection rationaleMost cited papers providing context for THCB pharmacology and the homolog series | |||
| 4document retrieval | HandWiki | — | 1 result, 1 selected |
selection rationaleselection rationaleConfirmed PubChem CID and provided structured chemical data | |||
| 5cross reference | Crossref / DOI verification | doi:10.1021/acs.jnatprod.9b00876 | 1 result, 1 selected |
selection rationaleselection rationalePrimary isolation paper DOI verified | |||
| 6literature search | PubMed | delta-9-THC cannabinoid CYP2C9 CYP3A4 metabolism pharmacokinetics | 8 results, 6 selected |
selection rationaleselection rationaleTHC CYP metabolism data extrapolatable to THCB by structural analogy | |||
| 7literature search | PubMed | minor cannabinoid neuropathic pain analgesic neuronal hypersensitivity | 1 result, 1 selected |
selection rationaleselection rationaleDirect testing of minor cannabinoids including THCB for analgesic effects | |||
| 8legal status search | WebSearch | tetrahydrocannabutol THCB legal status scheduling DEA United Kingdom EU | 10 results, 1 selected |
selection rationaleselection rationaleLegal status across major jurisdictions | |||
| 9legal status search | WebSearch | THCB tetrahydrocannabutol Canada Controlled Drugs and Substances Act | 10 results, 0 selected |
selection rationaleselection rationaleCanada status unresolved - analog provisions may apply | |||
| 10literature search | OpenAlex | THCB tetrahydrocannabutol cannabinoid pharmacology analgesic | 8 results, 2 selected |
selection rationaleselection rationaleExpands cannabinoid homolog series context and provides biosynthesis production alternative | |||
| 11literature search | PubMed | THC pharmacokinetics review bioavailability oral inhalation absorption distribution metabolism | 3 results, 3 selected |
selection rationaleselection rationaleTHC PK data for by-analogy extrapolation to THCB | |||
| 12legal status search | GOV.UK / ACMD | — | 1 result, 1 selected |
selection rationaleselection rationaleKey finding for UK legal status of THCB | |||
| 13clinical trial search | ClinicalTrials.gov | tetrahydrocannabutol THCB minor cannabinoid | 0 results, 0 selected |
selection rationaleselection rationaleConfirms no clinical trial development for THCB to date | |||
| 14web search | WebSearch | THCB effects user reports duration onset dose Reddit forum experience | 10 results, 1 selected |
selection rationaleselection rationaleOnly available dose/duration data - flagged as user-report-only | |||
| 15legal status search | WebSearch | Australia THCB Poisons Standard tetrahydrocannabinols homologs | 10 results, 1 selected |
selection rationaleselection rationaleAustralian legal status determination | |||
Research document (raw, unedited pipeline output)
# Research Output: Tetrahydrocannabutol (Δ9-THCB)
**PSX ID:** PSX-0351
**Substance slug:** tetrahydrocannabutol
**Characterization:** Emerging phytocannabinoid / minor cannabinoid
**Research completed:** 2026-05-11
---
## Chemical Identity
**Verified from PubChem CID 6453891 and HandWiki [Refs 9, PubChem direct lookup]:**
| Property | Value |
|---|---|
| Preferred name | Δ9-Tetrahydrocannabutol (Δ9-THCB) |
| Common abbreviation | THCB, THC-B, THC-C4 |
| Molecular formula | C₂₀H₂₈O₂ |
| Molecular weight | 300.4 g/mol |
| IUPAC name | (6aR,10aR)-3-butyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol |
| SMILES | CCCCC1=CC2=C([C@@H]3C=C(CC[C@H]3C(O2)(C)C)C)C(=C1)O |
| InChIKey | QHCQSGYWGBDSIY-HZPDHXFCSA-N |
| CAS number | 60008-00-6 |
| PubChem CID | 6453891 |
| ChEMBL | ChEMBL4437290 |
| ChemSpider | 4956237 |
| UNII | LIC9QAS59U |
**Brief not discrepancy:** The substance brief contained no pre-populated chemical data (all fields empty). The above data is newly verified against PubChem CID 6453891. The PubChem API confirmed: formula C₂₀H₂₈O₂, MW 300.4, InChIKey QHCQSGYWGBDSIY-HZPDHXFCSA-N, and IUPAC name.
**Structural relationship to THC:**
Δ9-THCB differs from Δ9-THC (C21H30O2, CID 16078) solely by the alkyl side chain at C-3: THC bears a pentyl (C5) chain, while THCB bears a butyl (C4) chain. This structural homology places THCB one carbon shorter than THC in the alkyl side-chain series (C1: THC-C1/cannabiorcol → C3: THCV → C4: THCB → C5: THC → C6: THCH → C7: THCP). Both delta-8 (Δ8-THCB) and delta-9 (Δ9-THCB) isomers have been identified in internet-sold products [Ref 4].
**Melting point / solubility:** No published data located.
**Optical rotation:** (−)-trans configuration confirmed by stereoselective synthesis and ECD (Linciano et al. 2020 [Ref 1]).
---
## Pharmacology
### Receptor Binding
The primary pharmacological characterization was published by Linciano et al. (2020 [Ref 1]) from the University of Modena and Reggio Emilia, Italy. Competitive radioligand binding assays against human CB1 and CB2 receptors gave:
- **CB1 receptor:** Ki = 15 nM
- **CB2 receptor:** Ki = 51 nM
These values are described as "comparable to that of (−)-trans-Δ9-THC" [Ref 1]. For context, Δ9-THC typically shows CB1 Ki values of approximately 5–35 nM depending on assay conditions; the companion THCP paper from the same group reported THC's CB1 Ki at ~10 nM under their assay protocol [Ref 2].
The C4 butyl side chain is one carbon shorter than THC's C5 pentyl chain. SAR data from Huffman et al. (2003 [Ref 25]) on Δ8-THC dimethylalkyl analogs demonstrated that C3–C10 side chains all support high CB1 affinity, with optimal affinity requiring the side chain terminus to fold back toward the phenolic ring. A C4 butyl chain is within this optimal range, consistent with the high affinity observed.
**Docking studies:** Molecular docking in the Linciano 2020 paper identified the key hydrogen bond interactions responsible for THC-like CB1 binding affinity [Ref 1].
### Functional Activity (In Vivo)
**Tetrad test (mice):** Linciano et al. (2020 [Ref 1]) subjected Δ9-THCB to the standard cannabinoid tetrad (hypolocomotion, catalepsy, antinociception, hypothermia). Δ9-THCB showed **partial agonistic activity toward the CB1 receptor** — it produced cannabimimetic effects but with less full-agonist efficacy than reference full agonists. This contrasts with Δ9-THCP (C7 chain, Ki = 1.2 nM), which produced a complete tetrad response [Ref 2].
**Formalin test (mice):** In vivo formalin testing demonstrated that Δ9-THCB possesses **analgesic and anti-inflammatory properties** [Ref 1]. The formalin model measures both acute (early phase, neurogenic) and inflammatory (late phase) pain responses. Specific dose data and phase-specific results are not reported in the available abstract; full paper access would be needed.
### Additional Pharmacological Activity
**SARS-CoV-2 main protease (Mpro) inhibition:** Liu et al. (2022 [Ref 5]) screened a library of minor cannabinoids against SARS-CoV-2 Mpro. Tetrahydrocannabutol was the **most active Mpro inhibitor in the library** (IC₅₀ = 3.62 µM), outperforming cannabigerolic acid (IC₅₀ = 14.40 µM). Surface plasmon resonance and molecular docking characterized binding interactions. This finding suggests non-cannabinoid-receptor pharmacology, though in vitro IC₅₀ values in the micromolar range have uncertain clinical relevance.
**Neuronal hypersensitivity (in vitro):** Anand et al. (2025 [Ref 14]) included THCB among ten minor cannabinoids tested in an in vitro model of neuronal hypersensitivity relevant to neuropathic pain. Full quantitative results are not available from the abstract, but the study suggests analgesic modulation at peripheral pain pathways.
**Non-CB receptor targets:** Phytocannabinoids with similar structures to THC can interact with TRPV1, TRPV2, GPR55, GPR18, GABAAR, and voltage-gated sodium channels [Ref 12]. No THCB-specific data on these targets has been published; effects on these targets remain uncharacterized and are inferred from cannabinoid class membership.
### Pharmacokinetics
**No published human or animal pharmacokinetic data exist for THCB.** The following is inferred from structural analogy with Δ9-THC — all values are flagged as class-inference, not THCB-specific data.
By analogy with Δ9-THC [Refs 16, 17, 19, 20, 21]:
- **Absorption (inhaled):** THC bioavailability ~25–30% via smoking; Tmax ~10 min; peak plasma ~160 ng/mL
- **Absorption (oral):** THC bioavailability 4–12%, highly variable; Tmax 1–6 hours; longer duration due to formation of active 11-OH-THC metabolite
- **Distribution:** Highly lipophilic; widely distributed; body fat serves as long-term storage reservoir; <1% of dose reaches brain at peak
- **Metabolism (THC):** Primarily CYP2C9 (intestinal and hepatic) to 11-hydroxy-THC (active metabolite), then to 11-nor-9-carboxy-THC (inactive). CYP3A contributes especially in fetal liver. THCB's butyl chain analog would be expected to undergo analogous C-11 hydroxylation and carboxylation [Refs 16, 17]
- **Elimination:** Via feces and urine; metabolites persist for weeks in chronic users
- **Half-life:** THC terminal half-life ~20–30 hours due to redistribution from fat stores
⚠️ **FLAG (safety-critical):** All pharmacokinetic parameters above are derived from Δ9-THC data by structural analogy. No published ADME studies for THCB exist. CYP enzyme involvement for THCB specifically has not been characterized.
### Drug-Drug Interactions
No THCB-specific interaction data exists. By analogy with Δ9-THC [Refs 16, 22]:
- CYP2C9 inhibition (competitive) — clinically relevant oral interactions predicted for warfarin, diclofenac, and other CYP2C9 substrates
- CYP3A4 inhibition (moderate)
- CYP2B6 inhibition
- Clinically relevant grapefruit-type warnings apply (CYP3A4 substrates)
- Δ8-THC analogs show competitive inhibition of CYP2C9 and CYP3A4 [Ref 16], further supporting this by-analogy inference
CNS depressant pharmacodynamic interactions expected (additive sedation with benzodiazepines, opioids, alcohol, other cannabinoids).
---
## History
**Discovery and first isolation:**
Δ9-THCB was first isolated, fully characterized, and pharmacologically evaluated by **Linciano, Citti, Luongo, Belardo, Maione, Vandelli, Forni, Gigli, Laganà, Montone, and Cannazza** (2020, Journal of Natural Products [Ref 1]) from the Italian medicinal Cannabis sativa FM2 variety, a pharmaceutical-grade cannabis cultivar produced by Italy's Military Chemical Pharmaceutical Institute. The paper was received in September 2019 and published online in January 2020 (DOI-verified publication year 2019 in Crossref metadata; PMID 31891265 indexed 2020 in PubMed — likely reflects online-first vs. journal-issue dating).
This discovery was part of a systematic effort by the same research group (University of Modena and Reggio Emilia and collaborators) to characterize minor phytocannabinoids in FM2. The same year, the group published isolation of cannabidibutol (CBDB, the CBD butyl analog) [Ref 10] and in 2019 had discovered Δ9-THCP (heptyl analog) [Ref 2]. In 2020, they further identified Δ9-THCH and CBDH (hexyl series) [Ref 11], completing a systematic phytocannabinoid homolog series from C3 (THCV/CBDV) to C7 (THCP/CBDP).
**Earlier synthetic work:**
Roger Adams' group at the University of Illinois synthesized early THC analogs in the 1940s, including compounds with varied alkyl chains. The claim that Adams specifically studied a butyl-chain THC analog in 1942 has been made in secondary sources but could not be confirmed from primary literature in this search. This requires editorial verification and should be treated as unverified until confirmed against Adams' original publications.
**Commercial emergence:**
Since approximately 2021, both Δ8-THCB and Δ9-THCB have appeared in internet-sold oil products including e-cigarette cartridges, herbal products, and edibles [Ref 4]. Products have been identified via forensic analysis in Japan (2022–2023) and in the United States. The Δ8-THCB isomer occurs as a semi-synthetic product, typically manufactured by Lewis acid-catalyzed isomerization starting from Δ8-THC or Δ9-THCB.
**Stereoselective synthesis:**
The Linciano et al. paper confirmed the structure and absolute configuration of (−)-trans-Δ9-THCB by stereoselective synthesis via direct condensation of 5-butylbenzene-1,3-diol (butylresorcinol) with (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol using Lewis acid catalysts, followed by HCl addition and base-catalyzed elimination — achieving 91% yield [web-retrieved secondary source, Ref 9; primary data in Ref 1].
**Microbial biosynthesis context:**
Yeast-based biosynthetic platforms have been developed for producing rare cannabinoids. While THCB has not been specifically targeted, these approaches are technically applicable and could serve as a route to obtain THCB without natural plant extraction [Ref 15].
---
## Subjective Effects
**No controlled human studies of Δ9-THCB exist.** All subjective effect data comes from:
1. In vivo animal pharmacology (tetrad and formalin tests in mice) [Ref 1]
2. User reports aggregated on commercial and harm reduction websites [Refs 18, 28]
3. The 2024 designer THC review, which references online forum reports [Ref 6]
**Animal model findings (mice):**
- Partial cannabimimetic effects in tetrad test (hypolocomotion, reduced rectal temperature, partial catalepsy, antinociception) [Ref 1]
- Less complete tetrad response than full agonists, consistent with partial agonism
- Analgesic and anti-inflammatory effects in formalin model [Ref 1]
**User-reported effects (label as user-report-only):**
- Euphoria, relaxation, mood elevation
- Analgesia / pain relief
- Enhanced focus and creativity ("clear-headed" quality)
- Mild-to-moderate body sensation
- Described as "slightly milder to comparable" to Δ9-THC; some users describe effects as more "functional"
- Reported onset: 30–60 minutes (described as a "creeper compound")
- Reported duration: approximately 4–8 hours
**Adverse effects from user reports:**
- Dry mouth and dry eyes
- Sedation / grogginess
- Dizziness / lightheadedness
- Impaired motor coordination
- Anxiety and paranoia (dose-dependent)
- Disorientation
- Excessive intoxication at higher doses
⚠️ **FLAG:** Duration and dose data above are from commercial vendor content and forum aggregation only. No controlled study data exists. These should be treated as user-report-only and flagged explicitly in the article.
---
## Safety & Toxicity
**No LD50, therapeutic index, organ toxicity, or overdose case report data is published for THCB.** No adverse event case reports specific to THCB were located in PubMed, OpenAlex, or general web search.
**By class analogy with Δ9-THC:**
- Cannabinoid class adverse effects: tachycardia, hypotension (brief), impaired cognition, anxiety, paranoia, psychosis risk in vulnerable individuals, impaired driving
- Repeated high-level use: CB1 receptor downregulation in brain regions, cognitive impairment
- Cannabis use disorder and withdrawal syndrome documented for THC class [Refs 27, and German review PMID 39134752]
- High-potency CB1 agonists (note: THCB is a partial agonist) can lower seizure threshold in susceptible individuals [Ref 12]
**Drug test cross-reactivity:**
The validated LC-MS/MS method of Muir et al. (2025 [Ref 3]) demonstrates that THCB can be qualitatively identified in blood and urine (LOD 1 ng/mL for blood). It is assumed that THCB generates metabolites (by analogy to THC's 11-OH-THCB and THCB-COOH forms) that would trigger standard immunoassay cannabinoid screens, though this has not been directly confirmed.
**Synthesis byproducts:**
Forensic analysis of internet products identified Δ¹¹-THCB as a minor synthesis byproduct of Δ8-THCB production [Ref 4]. The safety profile of Δ¹¹-THCB is unknown.
⚠️ **FLAG (safety-critical):** No LD50, human dose-response, or toxicological characterization data exists for THCB. All safety statements rely on class-level THC analogy. This is a significant data gap for an emerging market substance.
---
## Harm Reduction
- No published evidence-based harm reduction protocols specific to THCB
- By class analogy: avoid combination with CNS depressants (alcohol, benzodiazepines, opioids), avoid driving or operating machinery
- CYP3A4 and CYP2C9 interaction risk: users on anticoagulants (warfarin), antiepileptics (clobazam, carbamazepine), immunosuppressants (tacrolimus, cyclosporine), or other narrow-therapeutic-index drugs should avoid [Refs 20, 22]
- Standard harm reduction advice: start with low doses, wait adequately before redosing (especially for oral/edible formulations), avoid use in individuals with personal or family history of psychosis, schizophrenia, or bipolar disorder
- Products on the recreational market may contain Δ8-THCB (synthetic) and synthesis byproducts including Δ¹¹-THCB of unknown safety [Ref 4]
- Standard reagent test kits (Duquenois-Levine, Marquis) used for THC detection may indicate cannabinoid class membership but cannot distinguish THCB from THC
---
## Tolerance & Dependence
**No published THCB-specific tolerance or dependence data exists.**
By class analogy with Δ9-THC [Refs 26, 20]:
- CB1 receptor downregulation and desensitization develop with repeated high-dose cannabinoid use
- Tolerance to hypothermic effects of THC develops within days of repeated administration in mice; tolerance to locomotor effects is slower to develop [Ref 26]
- Cross-tolerance between THC and other CB1 agonists (including THCB) is expected; THC-tolerant individuals would likely show cross-tolerance to THCB [Ref 26]
- As a partial CB1 agonist, THCB may theoretically produce less tolerance and dependence than full CB1 agonists, analogous to how partial agonists at other GPCR targets show reduced tachyphylaxis — but this is speculative and not directly supported by any THCB data
**Cannabis use disorder analogy:** The Cochrane review on pharmacotherapies for cannabis use disorder [Ref 27] confirms no approved medications, behavioral interventions as first-line. Cannabinoid withdrawal syndrome (irritability, insomnia, anxiety, appetite disturbance, restlessness) documented for regular high-dose THC use; expected pattern for THCB by class analogy.
⚠️ **FLAG:** All tolerance and dependence data are class-inferences. The partial agonist status of THCB may modify the tolerance and dependence liability compared to THC, but this has not been studied.
---
## Interactions
| Interaction Type | Partners | Mechanism | Evidence Basis |
|---|---|---|---|
| CYP2C9 inhibition | Warfarin, diclofenac, phenytoin | Competitive inhibition | THC analogy [Refs 16, 22] ⚠️ FLAG |
| CYP3A4 inhibition | Midazolam, tacrolimus, cyclosporine, many others | Competitive inhibition | THC analogy [Refs 16, 20] ⚠️ FLAG |
| CYP2B6 inhibition | Bupropion, cyclophosphamide | Competitive inhibition | THC analogy [Ref 22] ⚠️ FLAG |
| CNS depressant additive | Alcohol, benzodiazepines, opioids, other cannabinoids | Pharmacodynamic | Class inference [Ref 20] |
| Sympathomimetics | Amphetamines, cocaine | Additive tachycardia, hypertension risk | Class inference [Ref 20] |
| Antipsychotics | Haloperidol, risperidone | Opposing/attenuating effects on dopaminergic system | Class inference |
⚠️ **FLAG (safety-critical):** All drug interaction data are class-inferences from THC pharmacology. No THCB-specific in vitro or human interaction studies have been performed.
---
## Legal Status
| Jurisdiction | Status | Notes |
|---|---|---|
| **United Kingdom** | Class B (controlled) | Covered under MDA 1971 generic text: "3-alkyl homologues of cannabinol or of its tetrahydro derivatives" [Ref 29]. ACMD 2025 confirmed THC homologs are already Class B without explicit listing |
| **Czech Republic** | Explicitly banned | Added to prohibited substance list July 2024 [web search] |
| **France** | Controlled | Covered under ban on cannabinoids with "benzo[c]chromene-type chemical nucleus" [web search] |
| **Australia** | Likely Schedule 8 (controlled) | Poisons Standard defines controlled tetrahydrocannabinols as including "all alkyl homologues"; THCB as an alkyl homologue would fall within this definition [Ref 9, web search] ⚠️ FLAG: Verify exact Poisons Standard wording |
| **United States** | Legal grey area | Not explicitly scheduled under CSA; naturally-occurring in cannabis (controlled), but hemp-derived THCB and synthetic THCB status unclear; DEA interim final rule on synthetically-derived THC analogs may apply |
| **Canada** | Not explicitly scheduled | CDSA Schedule II covers cannabis/THC and analogs; potential analog liability as a THC homolog; no specific listing confirmed |
| **International (UN Conventions)** | Not internationally scheduled | Not listed under the Convention on Psychotropic Substances [Refs 9, 29] |
| **Belgium, Poland, Estonia, Finland, Bulgaria** | Unclear / potentially legal grey area | Countries with THC-like cannabinoid restrictions but lacking specific THCB listing [web search] |
---
## Clinical Trials
No clinical trials for Δ9-THCB (tetrahydrocannabutol) were found on ClinicalTrials.gov. No phase I, II, or III studies have been registered. THCB remains at the preclinical discovery stage, with only in vitro binding data and mouse model experiments published.
---
## Community Feedback Analysis
No community feedback submitted (Part A2 of the brief was empty).
---
## Gaps & Flags
### Critical Data Gaps
1. **No human pharmacokinetic data** — No bioavailability, Tmax, half-life, or plasma concentration data for THCB in any species other than in vivo mouse tetrad data. All PK values are inferred from Δ9-THC by structural analogy. ⚠️ SAFETY-CRITICAL FLAG.
2. **No human dose-response data** — No controlled studies. Dose guidance in public domain is entirely from commercial vendors (user-report level). No therapeutic window established.
3. **No LD50 or acute toxicity data** — Not published for any species. ⚠️ SAFETY-CRITICAL FLAG.
4. **No withdrawal characterization** — Whether repeated THCB use produces a withdrawal syndrome has not been studied.
5. **No drug interaction studies** — All CYP interaction claims are class-level inferences from THC. ⚠️ SAFETY-CRITICAL FLAG.
6. **Partial agonist activity incompletely characterized** — The Linciano 2020 paper reports partial agonist activity in the tetrad test, but intrinsic efficacy, dose-response curves, and ceiling effect data are not available in the abstract.
7. **Δ8-THCB vs. Δ9-THCB pharmacology comparison** — Products on the market contain Δ8-THCB (semi-synthetic). Δ8-THCB has not been separately characterized for CB1/CB2 binding affinity or in vivo activity; differences from the natural Δ9 isomer are unknown.
8. **Δ¹¹-THCB synthesis byproduct** — Identified in forensic samples of Δ8-THCB products [Ref 4]. Safety profile entirely unknown.
9. **Melting point, solubility, and physical-chemical data** — Not located in any source.
10. **No formal metabolite identification for THCB** — The structure of 11-OH-THCB and THCB-COOH analogs is inferred but not confirmed experimentally.
### Source Quality Flags
- **Roger Adams 1942 butyl THC analog claim**: Multiple secondary sources state Adams studied butyl THC analogs in 1942; this could not be confirmed against primary Adams literature in this search. Should be treated as unverified until confirmed.
- **User report dose/duration data (Refs 18, 28)**: Commercial vendor sources only; not peer-reviewed. Suitable for characterizing what circulates in user communities but cannot be used as clinical guidance.
- **Australian Poisons Standard coverage**: Inferred from generic "all alkyl homologues of tetrahydrocannabinols" language; exact Poisons Standard schedule entry text should be verified against the current Poisons Standard document before asserting Schedule 8 status.
- **All CYP interaction data and PK parameters marked with ⚠️ FLAG** — structural analogy to THC, not THCB-specific.
### Contradictions Between Sources
None identified. Seed data in brief was empty (no pre-existing data to contradict). Published literature is internally consistent.
---
## Reference List
[Ref 1] Linciano P et al. (2020) Journal of Natural Products — primary isolation of Δ9-THCB; CB1 Ki=15 nM, CB2 Ki=51 nM; formalin test; tetrad test
[Ref 2] Citti C et al. (2019) Scientific Reports — THCP discovery; SAR context for THCB; tetrad methodology
[Ref 3] Muir LS et al. (2025) Journal of Analytical Toxicology — LC-MS/MS method for THCB in blood/urine
[Ref 4] Tanaka R & Kikura-Hanajiri R (2024) Yakugaku Zasshi — Δ8- and Δ9-THCB in internet products; Δ¹¹-THCB byproduct
[Ref 5] Liu C et al. (2022) Molecules — SARS-CoV-2 Mpro inhibition IC₅₀=3.62 µM
[Ref 6] Caprari C et al. (2024) Journal of Cannabis Research — designer THC review; THCB in recreational market
[Ref 7] Filipiuc LE et al. (2021) Pharmaceutics — phytocannabinoids beyond CB1/CB2; THCB context
[Ref 8] Caprioglio D et al. (2022) Biomolecules — minor phytocannabinoid review; dark cannabinome
[Ref 9] HandWiki Tetrahydrocannabutol — chemical identifiers; CAS 60008-00-6; legal status overview
[Ref 10] Citti C et al. (2019) J Pharm Biomed Anal — cannabidibutol (CBDB) isolation and characterization
[Ref 11] Linciano P et al. (2020) Scientific Reports — cannabidihexol / THCH isolation; THCB in homolog series
[Ref 12] Senn L et al. (2020) Pharmaceuticals — phytocannabinoid receptor/channel targets in epilepsy
[Ref 13] Oultram JMJ et al. (2021) Biomedicines — Cannabis sativa beyond CBD and THC
[Ref 14] Anand U et al. (2025) Journal of Pain Research — minor cannabinoids in neuronal hypersensitivity model
[Ref 15] Yan C et al. (2024) J Ind Microbiol Biotechnol — microbial biosynthesis of rare cannabinoids
[Ref 16] Bansal S et al. (2022) Drug Metab Dispos — comprehensive CYP P450 cannabinoid interaction predictions
[Ref 17] Kumar AR et al. (2022) Drug Metab Dispos — extrahepatic THC metabolism; CYP2C9 primary in intestine
[Ref 18] Canatura THCB guide — production, effects, legal status; user experience reports
[Ref 19] McGilveray IJ (2005) Pain Res Manag — cannabinoid pharmacokinetics review
[Ref 20] Lucas C et al. (2018) Br J Clin Pharmacol — cannabinoid PK/PD; contraindications; start-low-go-slow
[Ref 21] Goullé JP & Guerbet M (2014) Bull Acad Natl Med — THC PK; synthetic cannabinoids
[Ref 22] Nasrin S et al. (2021) Drug Metab Dispos — cannabinoid metabolites as CYP inhibitors
[Ref 23] André CM et al. (2016) Front Plant Sci — Cannabis sativa phytochemical diversity
[Ref 24] Gülck T & Møller BL (2020) Trends Plant Sci — phytocannabinoid biosynthesis
[Ref 25] Huffman JW et al. (2003) Bioorg Med Chem — SAR for dimethylalkyl-Δ8-THC series; C4 chain potency
[Ref 26] Tai S et al. (2015) Pharmacol Res — THC tolerance; CB1 downregulation; cross-tolerance
[Ref 27] Spiga F et al. (2025) Cochrane Database Syst Rev — pharmacotherapies for cannabis use disorder
[Ref 28] Binoid CBD — THCB side effects article; dosing guidance
[Ref 29] UK ACMD 2025 — covering letter on semi-synthetic cannabinoids; THC homologs Class B under MDA generic text